BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21232656)

  • 1. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
    Yuan CM; Stetler-Stevenson M
    Semin Hematol; 2011 Jan; 48(1):32-8. PubMed ID: 21232656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.
    Raja KR; Kovarova L; Hajek R
    Br J Haematol; 2010 May; 149(3):334-51. PubMed ID: 20201947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.
    Frébet E; Abraham J; Geneviève F; Lepelley P; Daliphard S; Bardet V; Amsellem S; Guy J; Mullier F; Durrieu F; Venon MD; Leleu X; Jaccard A; Faucher JL; Béné MC; Feuillard J;
    Cytometry B Clin Cytom; 2011 May; 80(3):176-85. PubMed ID: 21520405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparameter immunophenotyping by flow cytometry as a diagnostic tool in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Carulli G; Ottaviano V; Cannizzo E; Giuntini S; Manetti C; Ciancia EM; Azzarà A
    Clin Ter; 2012; 163(5):387-92. PubMed ID: 23099966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
    Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
    Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
    Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
    Sezer O; Heider U; Zavrski I; Possinger K
    Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
    Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
    Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma.
    Olteanu H; Harrington AM; Kroft SH
    Am J Clin Pathol; 2012 Dec; 138(6):867-76. PubMed ID: 23161721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
    Tembhare PR; Yuan CM; Venzon D; Braylan R; Korde N; Manasanch E; Zuchlinsky D; Calvo K; Kurlander R; Bhutani M; Tageja N; Maric I; Mulquin M; Roschewski M; Kwok M; Liewehr D; Landgren O; Stetler-Stevenson M
    Leuk Res; 2014 Mar; 38(3):371-6. PubMed ID: 24462038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
    Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
    Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.
    Manasanch EE; Salem DA; Yuan CM; Tageja N; Bhutani M; Kwok M; Kazandjian D; Carter G; Steinberg SM; Zuchlinski D; Mulquin M; Calvo K; Maric I; Roschewski M; Korde N; Braylan R; Landgren O; Stetler-Stevenson M
    Leuk Lymphoma; 2015 May; 56(5):1416-24. PubMed ID: 25263319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Benign monoclonal gammopathy].
    Shirota T; Kondo M; Uchida H; Ito H
    Nihon Rinsho; 1995 Mar; 53(3):720-4. PubMed ID: 7699912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.
    Paiva B; Almeida J; Pérez-Andrés M; Mateo G; López A; Rasillo A; Vídriales MB; López-Berges MC; Miguel JF; Orfao A
    Cytometry B Clin Cytom; 2010 Jul; 78(4):239-52. PubMed ID: 20155853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.